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Key Messages 34 
1. The degranulation and maturation of human mucosal-type mast cells is controlled 35 
by cannabinoid receptor (CB)-1. This is clinically relevant in the context of the 36 
aetiopathology of nasal polyps. 37 
2. CB1 may be a new target in the management of diseases in human bronchial 38 
mucosa including allergic rhinitis and bronchial asthma. 39 
 40 
Capsule summary 41 
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Human nasal polyp organ-culture offers a clinically relevant model for investigating 42 
human mucosal-type mast cells (hMMC) in situ. We show that hMMC activation and 43 
maturation from resident progenitors is constitutively controlled by endocannabinoids 44 
via CB1.  45 
 46 
Key words Nasal polyp, mucosa, organ culture, endocannabinoid, cannabinoid 47 
receptor, mast cell, SCF, c-Kit, tryptase, chymase 48 
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MC   mast cell 51 
NP   nasal polyp 52 
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ABSTRACT  57 
Background: Since many chronic inflammatory and allergic disorders are intimately 58 
linked to excessive mast cell (MC) number and activation, it is clinically important to 59 
understand the physiological mechanisms preventing excess MC 60 
accumulation/degranulation in normal human tissues.  61 
Objective: Since endocannabinoids are increasingly recognized as neuroendocrine 62 
regulators of MC biology, we investigated how cannabinoid 1 (CB1) receptor-signaling 63 
affects human mucosal-type MCs (hMMCs). 64 
Methods: Using organ-cultured nasal polyps (NP) as a surrogate tissue for human 65 
bronchial mucosa, we investigated by quantitative (immuno)histomorphometry and  66 
ultrastructurally how CB1 stimulation, inhibition or knock-down impacts hMMCs 67 
biology. 68 
Results: Kit+ hMMCs express functional CB1 in situ. Blockade of CB1-signaling 69 
(using specific CB1 antagonist, AM 251, or CB1 gene knock-down) enhanced hMMCs 70 
degranulation and increased their total number without affecting their proliferation in 71 
situ. This suggests that inhibiting CB1-signaling induces hMMC maturation from 72 
resident progenitor cells within human mucosal stroma. hMMCs maturation was 73 
induced at least in part via up-regulating stem cell factor (SCF) production. Both the 74 
prototypic endocannabinoid, anandamide, and the CB1-selective agonist, 75 
arachidonyl-2-chloroethylamide, effectively counteracted secretagogue-triggered 76 
excessive hMMCs degranulation. 77 
Conclusions: The current serum-free NP organ-culture model allows physiologically 78 
and clinically relevant insights into the biology and pharmacological responses of 79 
primary hMMCs in situ. In human airway mucosa, hMMCs activation and maturation 80 
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are subject to a potent inhibitory endocannabinoid tone via CB1 stimulation. This 81 
invites one to target the endocannabinoid system in human airway mucosa as a novel 82 
strategy in the future management of allergic diseases. 83 
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While the central role of human mucosal-type mast cells (hMMCs) in respiratory 84 
diseases, including allergic rhinitis and asthma, is well-appreciated,1,2 most research 85 
on hMMCs relies on isolated cells obtained during bronchial lavage or cell lines.3,4 86 
Instead, studies that examine and manipulate primary hMMCs within their natural 87 
tissue habitat, the respiratory tract mucosa, are scarce.5-7 However, it is crucial to 88 
study hMMC in situ, rather than in isolated cell culture, since MC functions (including 89 
activation, degranulation, maturation, proliferation and apoptosis) are critically 90 
influenced by their immediate tissue environment; vice versa, MCs greatly impact on 91 
the tissue they reside in, namely in the airways.8-12 For such in situ studies of hMMCs, 92 
nasal polyps (NPs) have long offered a very attractive, yet still regrettably 93 
under-appreciated assay options for clinically relevant in situ-MC research in the 94 
human system.5,6 95 
 96 
NPs represent polypoidal masses that arise mainly from nasal and paranasal mucous 97 
membranes and are frequently associated with allergic rhinitis and other “atopic” 98 
diseases.13,14 Since nasal mucosa forms one functional continuum with the upper 99 
respiratory tract mucosa,15,16 the organ culture of NPs can serve as an easily 100 
accessible, well-defined, and abundantly available surrogate tissue for – much less 101 
readily obtainable – bronchial mucosa and its hMMC populations.5,6 Moreover, hMMCs 102 
also play an important role in the pathogenesis of NP formation as such 2,5,17-19 so that 103 
MC research in organ-cultured NPs simultaneously allows one to investigate one of 104 
the most common clinical problems of upper respiratory tract medicine. 105 
Previous human NP organ culture models,3,20 are limited by relatively rapid NP decay 106 
and/or the presence of bovine serum in the culture medium, require special matrix 107 
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support systems, and/or have not systematically addressed key MC biology questions, 108 
such as the physiological controls of hMMC maturation and activation in situ. 109 
Therefore, we aimed to develop a very simple, serum-free organ culture system that i) 110 
prolongs NP tissue viability in vitro, and ii) permits the quantitatively study of key MC 111 
research parameters in situ, and iii) permits instructive functional and mechanistic 112 
studies, including pharmacological manipulations and gene-knock-down, of primary 113 
hMMCs in situ.  114 
 115 
As a potentially interesting system that may control hMMC functions, we turned to the 116 
endocannabinoid system (ECS). The ECS is composed of cannabinoid receptors 117 
(CBs), their endogenous ligands and enzymes responsible for endocannabinoid 118 
synthesis and degradation.21-25 Components of the ECS are increasingly recognized 119 
as important neuroendocrine regulator of MC biology.21,26-28 Notably, we have recently 120 
reported in this journal that the ECS limits excessive human skin MC activation and 121 
maturation via CB1-mediated signaling in situ.29 However, the role of CB-mediated 122 
signaling in hMMCs still remains largely unknown (see supplementary text S1). 123 
Therefore, we investigated the effects of CB1 stimulation/blockade on hMMCs biology 124 
within organ-cultured human nasal mucosa.  125 
 126 
METHODS 127 
Human nasal polyp (NP) organ culture 128 
Human NP samples were obtained from 5 males and 2 females (aged: 23-80, 129 
average: 41.4) undergoing elective surgery for nasal obstruction (polypectomy). 130 
Human tissue collection and handling was performed according to Helsinki guidelines, 131 
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with Institutional Research Ethics approval (University of Luebeck) and written 132 
informed consent. Freshly isolated NPs were cut into small pieces (6 x 6 x 6 -10 x 10 x 133 
10 mm) and maintained in supplemented serum-free William’s E medium.29-32 NPs 134 
were first incubated overnight to adapt to culture conditions after which the medium 135 
was replaced and vehicle or test substances were added. For the organ culture with 136 
substance P, compound 48/80 and corticotropin-releasing hormone (CRH), NPs were 137 
first treated with N-arachidonoylethanolamine (anandamide, AEA, 30 M) or 138 
arachidonyl-2-chloroethylamide (ACEA, 30 M) for 1 day after the overnight 139 
incubation. Then the NPs were treated with substance P (10-10 M) or compound 48/80 140 
(10 g/ml)29 or CRH (10-7 M)31 in the combination with AEA or ACEA for additional 1 141 
day. Following NP organ-culture for the indicated time, tissue was processed for cryo- 142 
or paraffin sections and histochemistry, immunohistochemistry, or transmission 143 
electron microscopy. Data from test and control groups within one set of experiments 144 
were generated by using only NPs from the same patient. 145 
 146 
CB1 knock-down 147 
CB1 silencing in organ-cultured human NPs was performed using the previously 148 
reported method.29 149 
 150 
Immunohistochemistry/Immunofluorescence microscopy 151 
For the detection of CB1, stem cell factor (SCF), Kit, high affinity IgE receptor 152 
(FcRI), tryptase and chymase immunohistochemistry, paraffin embedded sections 153 
were used. For the immunofluorescence study for Kit, CB1 and SCF, cryo-embedded 154 
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sections were also used (for details, see this article’s Methods section in the Online 155 
Repository).  156 
hMMCs were defined as “degranulated” when more than 5 histochemically or 157 
immunohistologically detectable MCs granules could clearly be observed outside the 158 
MC membrane (see representative degranulated MC in Fig. E1A).29,31 159 
 160 
Quantitative immunohistomorphometry and transmission electron microscopy 161 
(TEM)  162 
Quantitative immunohistomorphometry of the observed immunoreactivity patterns in 163 
defined reference areas were assessed according to the previously described 164 
principles 29-32 using the ImageJ software (National Institutes of Health, Bethesda, 165 
MD). TEM was done as previously reported.29 166 
 167 
Statistical Analysis 168 
Data were analyzed using either the Mann-Whitney U-test for unpaired samples or 169 
1-way ANOVA, Bonferroni's multiple comparison test, using Prism 4.0 software 170 
(GraphPad Prism Program, GraphPad, San Diego, CA). p values <0.05 were 171 
regarded as significant. All data in the Figure are expressed as mean + SEM. * 172 
P<0.05, ** P<0.01, *** P<0.001, comparing the indicated experimental groups. 173 
 174 
RESULTS 175 
Human NPs can be organ-cultured for at least 7 days 176 
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First, we adapted the long-term organ culture human skin30,31 to the organ culture of 177 
human NPs, using supplemented, serum-free William’s E medium. This simple and 178 
cost-efficient assay preserved NP architecture for at least 7 days (later time points 179 
were not examined). Even at day 7 after culture initiation, the NP tissue architecture 180 
and cellularity were reasonably well-preserved, and even mucosal cilia in the NP 181 
epithelium as well as blood vessels and collagen fibers of the NP stroma (lamina 182 
propria) were partially conserved (Fig 1A and B).  183 
After a temporary decline subsequent to the trauma of tissue dissection, at day 7, cell 184 
proliferation in the NP epithelium quickly recovered, and had reached again initial day 185 
0 levels (Fig 1C). In contrast, cell proliferation within the NP lamina propria remained 186 
stable throughout the examined organ culture period (Fig 1D). Although intermittently 187 
increased stroma cell apoptosis was observed at day 3 (Fig 1E), general tissue decay 188 
parameters (% of apoptotic [TUNEL+] cells, LDH release) also had stabilized by day 7 189 
(Fig 1E, F and E1B). However, with increasing organ-culture time, the NP stroma 190 
became slowly more edematous (Fig. 1A). This needs to be accounted for when 191 
calculating cell numbers per reference area in NP organ-culture. 192 
 193 
hMMCs are detectable histochemically and immunohistochemically in NP organ 194 
culture 195 
Multiple fully granulated (Fig 2A) or degranulated (Fig 2B) hMMC could be detected 196 
histochemically at all examined time points of NP organ culture. For this, Leder’s 197 
esterase [Fig 2A] or Giemsa [Fig 2A] or alkaline Giemsa histochemistry [Fig E1C] 198 
provided optimal cell visualization and morphological detail. Since the FcRI+ is not 199 
only expressed on hMMC (Fig 2A), but also e.g. on Langerhans cells, basophils, 200 
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platelets, eosinophils, monocytes and dendritic cells,33,34 FcRI+ proved to be a less 201 
instructive marker of mature hMMCs in NPs compared to classical MC histochemistry 202 
(toluidine blue, Leder’s esterase, Giemsa and alkaline Giemsa histochemistry, Fig 2A 203 
and Fig E1C) on the one hand, or tryptase (Fig 2A and B) or chymase 204 
immunohistochemistry (Fig 2A) respectively on the other.  205 
Most Kit+ cells in human NP stroma clearly represented hMMCs as indicated by 206 
co-expression of FcRI, and the majority of hMMCs in NP stroma was of the 207 
tryptase+/chymase- subtype (for details, see supplementary text S2 and Figs. E1D, 208 
E1E). 209 
 210 
Furthermore, to assess whether the number of hMMCs within the lamina propria 211 
varied during organ culture, tryptase or Kit (CD117)29,31 immunohistochemistry was 212 
performed. The number of tryptase+ hMMCs in the lamina propria was stable during 213 
NP organ culture (Fig E1F), while that of Kit+ hMMCs increased (Fig. E1G). In view of 214 
the slowly progressing NP edema (Fig. 1A), the number of tryptase+ hMMCs may 215 
actually have increased during organ-culture, while the observed numeric increase 216 
Kit+ hMMCs probably even exceeds the absolute values measured here. 217 
The percentage of cells positive for tryptase (which demarcates mature MCs) and Kit+ 218 
cells (which demarcates both immature MC and MC progenitors29,35,36) increased until 219 
day 7 (Figs. 2C and D). However, there was no significant increase in Kit+ cells 220 
proliferation (Ki67) (Fig E2A). This suggests that during NP organ-culture new, mature 221 
hMMCs differentiate in loco from resident progenitor cells. Interestingly, 222 
immunoreactivity for the Kit ligand, SCF, was still detectable in the NP epithelium at 223 
day 7 (Fig 2E). The continued presence of this key MC growth factor1,2,8,29 may 224 
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explain in part why hMMCs can be preserved in NPs during prolonged organ-culture 225 
without serum or exogenous growth factors, and why there is hMMC maturation from 226 
(preexisting) resident MC progenitors.  227 
 228 
hMMCs express functional CB1 229 
Next, we employed this simple, optimized, and serum-free, clinically relevant NP 230 
organ culture assay to investigate whether a new regulatory principle of human MCs 231 
that we had previously identified in human connective tissue-type MCs29 also applies 232 
to hMMC in situ. Namely, we had shown that the ECS limits both, the degranulation of 233 
mature connective tissue-type MCs and the local maturation of these MC from 234 
resident progenitor cells in human skin in situ via CB1 stimulation.29 However, the role 235 
of the ECS in hMMC biology in situ remains obscure, and whether a similar 236 
CB1-mediated “inhibitory tone” is also established in the control of primary hMMC 237 
activation and maturation within normal respiratory tract mucosa is completely 238 
unknown.  239 
Therefore, we first checked, whether Kit+ hMMCs in the NP lamina propria express 240 
CB1. This is the case (Fig 3A). Furthermore, stimulation with the highly CB1-selective 241 
ligand, Tocrifluor T111729 demonstrated functional binding activity of these receptor 242 
proteins with CB1-like IR for a cognate, specific ligand (Fig 3B).  243 
 244 
CB1 inhibition induces hMMCs degranulation and increases their number 245 
Just as in human skin MCs,29 the CB1-specific synthetic agonist, 246 
arachidonyl-2-chloroethylamide (ACEA)29,37 or the non-selective endocannabinoid 247 
Sugawara et al 
13 
 
CB1 agonist, anandamide (AEA),10,29,32 did not significantly increase the number of 248 
tryptase+ hMMC in human NPs (counted as number of tyrptase+ cells per visual field 249 
[Fig. E2B and C] and as %positive cells per total number of cell nuclei [Fig. 3C, D and 250 
E, Fig. E3]). hMMC degranulation was also unaffected by these CB1 agonists (Fig 3F 251 
and G, Fig. E4).  252 
In contrast, the specific CB1 antagonist, AM251,29,32 significantly increased both, the 253 
number (Fig. E2B and C, Fig. 3D and E, Fig. E3) and the degranulation of tryptase+ 254 
hMMCs in situ (Fig. 3C, F and G, Fig. E4). This was abrogated by the 255 
co-administration with ACEA or AEA (Fig 3D-G, Fig. E3 and 4). Increased hMMCs 256 
degranulation by CB1 specific antagonist was independently confirmed by high 257 
resolution light microscopy of alkaline Giemsa histochemistry (Fig. E1C and E2D) and 258 
by transmission electron microscopy (Fig. E2E).  259 
Since MCs degranulation typically induces mucosal edema,38,39 we next investigated 260 
the impact of the CB1 antagonist on NP edema. Indeed, AM251 decreased the 261 
cellularity (i.e. number of total nuclei/mm2) in the NP lamina propria compared to the 262 
control group (Fig. E6A and B) and thus NP edema, likely as a result as CB1 263 
blockade-induced MC degranulation. 264 
 265 
CB1 inhibition promotes the maturation of resident hMMC progenitors in NP 266 
stroma 267 
Intriguingly, AM251 also significantly increased the number and the percentage of Kit+ 268 
hMMCs in situ (Fig. E2G, Fig. 4A, Fig. E5, left panel]). However, just as in human skin 269 
MCs in situ,29 proliferation (Fig. 4B) or apoptosis (Fig. 4C) of hMMC did not change 270 
significantly after pharmacological CB1 blockade. Therefore, the increased number of 271 
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detectable mature hMMCs can only have arisen from resident progenitor cells. Since 272 
human nasal mucosa, besides tryptase+ hMMCs (Fig. 3D and E, Fig. E3), exhibits 273 
many chymase+ MCs,40 it is interesting to note that CB1 blockade also increased the 274 
number and the percentage of chymase+ hMMCs in situ (Fig. 4D, E2H, E5, right 275 
panel).  276 
Importantly, the impact of CB1 stimulation/blockade on hMMCs degranulation and 277 
numbers in situ was highly consistent between distinct NP assays derived from 4 278 
different patients (Fig. E3-5). For human tissue organ culture standards, where data 279 
variability - even between tissue samples derived from the same patient - can be 280 
substantial, the observed CB1 agonists/antagonist effects on hMMCs degranulation 281 
and on the percentage of Kit+, tryptase+ and chymase+ cells in situ are unusually 282 
robust and we—reproducible. This underscores the usefulness of the current human 283 
NP organ culture assay as a hMMC research model. 284 
 285 
CB1 blockade increases the number of hMMCs within the NP epithelium 286 
 hMMCs, which migrate towards and into the NP epithelium, may play an important 287 
role in NPs pathogenesis.41 42 Therefore, we asked whether CB1 stimulation/blockade 288 
also affects the location of hMMC within the NP. Interestingly, already after a single 289 
day of AM251 treatment the number of tryptase+ intraepithelial MCs was significantly 290 
increased compared to controls (Fig. 4E and F). This was partially abrogated by 291 
co-administration of the CB agonist, ACEA (Fig. 4F). This suggests that signaling 292 
through CB1, which is also expressed on NP epithelial cells (Fig. 5A see untreated 293 
skin), impacts on hMMC migration into the NP epithelium. 294 
 295 
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The CB1 gene can be silenced in organ-cultured human NPs 296 
Next, CB1 gene silencing was attempted, using the same protocol we had previously 297 
described for human hair follicles.29 Effective epithelial and mesenchymal CB1 298 
knock-down was demonstrated by a significant down-regulation of CB1 299 
immunoreactivity by 40% in the epithelium (Fig 5A and B), and on CB1+ stromal cells 300 
(Fig 5A and C) of organ-cultured NPs. Similar to the effects of pharmacological CB1 301 
blockade (Fig. 3D-G and Fig. 4A, D and E), CB1 gene silencing significantly increased 302 
the percentage of tryptase+ hMMCs in the lamina propria (Fig 5D) and stimulated their 303 
degranulation (Fig 5E). These data independently confirm that CB1 blockade induces 304 
hMMC maturation from resident progenitor cells and induces hMMC degranulation in 305 
situ not only in human skin mesenchyme29, but also in human respiratory tract 306 
mucosa. 307 
 308 
Endocannabinoids inhibit excessive activation of hMMCs via CB1 309 
Excessive MCs degranulation and numbers in human mucosa play a key role in the 310 
pathogenesis and clinical phenotype of major allergic diseases of the respiratory 311 
tract.1,7,33 Therefore, we then asked whether CB1 stimulation counteracts the 312 
MCs-activating effects of two classical endogenous MCs secretagogues that play a 313 
key role in MC-dependent neurogenic airway inflammation: substance P29,43-47 and 314 
corticotropin-releasing hormone (CRH).31,48 In addition, we examined the exogenous 315 
standard MC secretagogue, compound 48/80.29 316 
Quantitative tryptase-immunohistomorphometry demonstrated that both, the potent 317 
endocannabinoid AEA and the CB1-specific agonist, ACEA, inhibited the 318 
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degranulation-promoting effects of substance P (Fig. 6A), CRH (Fig. 6B) and 319 
compound 48/80 (Fig. 6C). Thus, exactly as in human skin MCs,29 CB1 stimulation 320 
effectively counteracts excessive MC activation in normal human mucosa in situ.  321 
 322 
CB1 regulates stem cell factor expression by the NP epithelium 323 
Since increased SCF production (along with enhanced number and degranulation of 324 
MCs) has been reported in the nasal epithelium of patients with allergy,49 we asked 325 
whether CB1 inhibition also affects SCF expression in human nasal mucosa in situ.  326 
 327 
Faint SCF-like immunoreactivity was detected within the NP epithelium at day 7 (Fig 328 
2G). Compared to the vehicle control group (Fig 7A, left photo), CB1 inhibition by 329 
AM251 significantly increased SCF-like immunoreactivity in the NP epithelium after 330 
only 1 day of NP organ culture (Fig 7A, right image and Fig 7B). Furthermore, the 331 
up-regulation of the number of tryptase+ hMMCs by pharmacological CB1 blockade 332 
(AM251) was completely abrogated by neutralizing SCF (Fig 7C). This suggests that 333 
enhanced hMMCs maturation by CB1 blockade in NPs in situ is mediated at least in 334 
part via up-regulation of SCF expression and increased SCF secretion by the NP 335 
epithelium.  336 
 337 
DISCUSSION 338 
Our data provide the first evidence that normal hMMCs utilize CB1-mediated signaling 339 
to limit not only their degranulation, but also their maturation from resident progenitor 340 
MC cells in situ. The observed effects of pharmacological or transcriptional CB1 341 
blockade may be induced not only directly via CB1 receptors on the cell membrane, 342 
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but also indirectly by up-regulating SCF-production within the NP epithelium in situ. 343 
These results underscore the key role of the ECS in human MC physiology, and 344 
confirm the importance of CB1-mediated signaling as an endogenous, “tonic” control 345 
system that avoids excessive MC maturation and degranulation, which we had 346 
previously identified for human connective tissue-type MCs in human skin.29  347 
This clinically and biologically important confirmation-of-concept in a different tissue 348 
system (human airway mucosa versus skin) is complemented by additional novel 349 
insights: 350 
1. The current study closes an important gap in the human MC biology literature 351 
by clarifying the effect of CB1-mediated signaling on normal primary hMMCs in situ. 352 
2. CB1 signaling (both, via directly impacting on MCs membrane receptor and 353 
indirectly via controlling epithelial SCF secretion) has a universal regulatory effect not 354 
only on human connective tissue-type, but also on hMMCs in situ, and is no peculiarity 355 
of the hair follicle-associated MCs we had investigated before.29 356 
3. Our demonstration that CB1 blockade increases the number of intraepithelial 357 
MCs in NPs (Fig. 4E and F) shows that CB1 signaling also regulates hMMC location 358 
and migration.  359 
4. We show that serum-free human NP organ culture provides a very instructive, 360 
clinically relevant model system that generates robust and well-reproducible data for 361 
investigating the biology of hMMCs and their response to pharmacological 362 
manipulation in situ. However, apoptosis as well as increased hMMC maturation from 363 
resident progenitor cells do occur in this ex vivo system. Therefore, even though adult 364 
primary hMMCs do operate within their natural tissue habitat in this assay, NP organ 365 
culture as such impacts MC biology in situ and cannot be entirely equated with the 366 
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physiological in vivo situation. Yet, the translational relevance of human NP organ 367 
culture for clinical respiratory medicine surely exceeds that of mainstream mucosal 368 
MC research that relies on mouse in vivo models and human cell lines. 369 
5. Our assay system also allows instructive studies on how MC secretagogues 370 
and MC degranulation inhibitors impact the physiology and pathology of human 371 
airway mucosa in situ.  372 
Systematic exploitation of this NP assay may also shed new light on the as yet 373 
unclear role of hMMCs in NP pathogenesis.41,42,49 Moreover, our findings raise the 374 
possibility that insufficient CB1-mediated signaling (e.g. in the epithelium) triggers 375 
excessive, SCF-mediated influx of hMMC into the epithelium of nasal mucosa. This 376 
may be relevant not only to NP pathogenesis, but also to other hMMCs-dependent 377 
human airway pathologies. If the ECS indeed operates (e.g. via CB1 signaling) as a 378 
safeguard system against excessive epithelial SCF production and secretion (to limit 379 
undesired MC maturation, activation, and migration into/towards the epithelium), the 380 
future management of allergic upper airway diseases could profit from re-establishing 381 
effective CB1-mediated signaling (e.g., up-regulation of intramucosal 382 
endocannabinoid levels by inhibition of their degradation by FAAH inhibitors23-25). 383 
 384 
We were surprised to find fewer Kit+ MCs than tryptase+ or chymase+ MCs (Fig. 2C 385 
and D, Fig. E5, patients 1 and 2), since Kit is often interpreted as a universal marker 386 
for detecting both immature and mature MCs.50 However, only 70-90% of tryptase+ 387 
cells in human samples from stomach, colon, and breast tissue reportedly are Kit+.51 388 
In line with this, the percentage of Kit+ MCs in the lamina propria of NPs from some 389 
patients was lower than that of tryptase+ or chymase+ hMMCs (Fig. E3 and 5). 390 
Moreover, besides MCs, basophils (which are Kit-negative,52 yet can be a prominent 391 
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feature of NP immunopathology53) all can be tryptase-positive.54 Taken together, this 392 
may explain the lower number of Kit+ MCs compared to that of tryptase+ or chymase+ 393 
MCs in organ-cultured NPs and shows that Kit has inherent limitations as a “universal” 394 
marker for hMMCs, also in human NPs. 395 
 396 
Fully in line with our previous results obtained from human skin MCs,26 CB1 blockade 397 
significantly increased the number of total Kit+ hMMCs without modifying their 398 
proliferation or apoptosis in organ cultured NPs (Fig. 4B and C). Although Kit 399 
demarcates both immature and mature MCs,50 there are no selective markers for 400 
immature hMMC progenitors, and some trytase+ hMMC do not even express Kit in 401 
situ.51 In fact, Kit-negative MC progenitors have previously been reported in human 402 
peripheral blood,55 and their existence has been deduced from morphometric data in 403 
the connective tissue sheath of human scalp HFs.29,31 This renders it likely that Kit- 404 
MC progenitors also exist in human NPs.  405 
In the NPs of some patients, the number of Kit+ MCs was even lower than that of 406 
tryptase+ or chymase+ MCs (Fig. E3 and 5). Therefore, the number of MC progenitors 407 
in NPs cannot be reliably estimated by simply subtracting the number of tryptase+ MC 408 
from that of Kit+ MCs. However, the percentage of Kit+ MCs increased significantly 409 
during organ culture (Fig. 2D). Moreover, there were no indications of significant CB1 410 
antagonist-induced proliferation of Kit+ progenitor cells. Instead, the number of 411 
mature hMMCs (i.e. hMMCs expressing the differentiation-associated proteins 412 
tryptase and chymase) rose significantly. Since the isolated NP samples had no 413 
connection to the bone marrow or vasculature, these unequivocal findings can only be 414 
explained by the differentiation of at least some resident MC progenitor cells into 415 
mature MCs.  416 
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That co-administration of CB1 agonists counteracted the CB1 blockade-induced 417 
excessive hMMC maturation (Fig. 3D and E, Fig. 4A and D) supports a key role for 418 
CB1 in controlling not only human MC degranulation in situ, but also MC maturation 419 
from resident progenitors. Although there was a slight tendency to increased MC 420 
numbers and degranulation upon CB1 agonist stimulation (Fig. 3D-G), this was not 421 
significant. Furthermore, CB1 antagonist-induced hMMC degranulation was greatly 422 
reduced by CB1 agonists (Fig. 6A-C). This supports the general concept that “tonic” 423 
CB1 stimulation is primarily required to prevent excessive hMMC degranulation and 424 
maturation.29425 
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Figure Legend (60 words per each legend) 595 
 596 
FIG 1. Human NP organ culture 597 
PAS (A) and modified Verhoeff Van Gieson (B) histochemistry. Quantitative 598 
immunohistomorphometry of (C) Ki67 in the epithelium and (D) lamina propria, (E) 599 
TUNEL in lamina propria and (F) epithelium. BM=basement membrane, BV= blood 600 
vessel, CF= collagen fibers. Data were obtained from 3 individuals. *P<0.05, **P<0.01, 601 
***P<0.001. N.S.=not significant. 602 
 603 
FIG 2. hMMCs in organ cultured human NPs 604 
(A) hMMCs histochemistry and immunohistochemistry. (B) Representative image of 605 
degranulated tryptase+ hMMC. Quantitative tryptase (C)-, Kit (D)- 606 
immunohistomorphometry. (E) SCF immunohistochemistry. Arrows: positive cells. 607 
Arrow in (E): positive immunoreactivity. Data from 3 individuals. *P<0.05, **P<0.01.   608 
 609 
FIG 3. hMMCs express functional CB1 in situ 610 
(A) Kit/CB1 double immunofluorescence. Yellow arrow: double+ immunoreactivity. (B) 611 
Kit (green) immunofluorescence with organ cultured NP treated with Tocrifluor (red). 612 
Representative images of tryptase-immunohistochemistry (C). Yellow arrow: 613 
non-degranulated hMMC. Red arrows: degranulated hMMCs. Quantitative 614 
immunohistomorphometry of tryptase (D and E), %degranulation (F and G).  615 
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Data from 3 individuals. *P<0.05, **P<0.01, ***P<0.001. There was no significant 616 
difference between control and AEA/ACEA. 617 
 618 
FIG 4. CB1 inhibition induces hMMC maturation but not proliferation 619 
(A) Quantitative immunohistomorphometry of Kit. (B) %Ki67+ Kit+ cells in organ 620 
cultured human NPs. (C) %TUNEL+ Kit+ cells in organ cultured human NPs. (D) 621 
Quantitative immunohistomorphometry of chymase. (E) Representative images of 622 
tryptase+ hMMCs in the epithelium. (F) Quantitiative analysis of intraepithelial hMMCs. 623 
These experiments were from 3 individuals. **P<0.01, ***P<0.001, N.S.=not 624 
significant. 625 
 626 
FIG 5. CB1 blockade by gene knock-down increases hMMC number and induces 627 
degranulation in situ 628 
(A) CB1 immunohistochemistry. TFE=transfection reagent-, SCR=scrambled siRNA-, 629 
CB1 siRNA=CB1 siRNA- treated NPs. Quantitative analysis of relative CB1 630 
immunoreactivity within the epithelium (B) and CB1+ mesenchymal cells (C). 631 
Percentages of tryptase+ (D) and degranulated (E) hMMCs among TFE, SCR or CB1 632 
siRNA treated NPs. These experiments were from 2 individuals. *P<0.05, **P<0.01, 633 
***P<0.001. 634 
 635 
FIG 6. CB1 stimulation inhibits hMMCs degranulation by MC secretagogues 636 
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Percentage of degranulated tryptase+ hMMCs in organ cultured human NPs after 637 
stimulation with MC secretagogues, substance P (A, 10-10M), compound 48/80 (B, 10 638 
g/ml) and CRH (C, 10-7M) in combination with AEA (30 M) or ACEA (30 M). AEA 639 
or ACEA clearly inhibited hMMC degranulation by various MC secretagogues. 640 
*P<0.05, **P<0.01, ***P<0.001. These experiments were from 2 individuals. 641 
 642 
FIG 7. CB1 inhibition increases SCF expression in situ 643 
(A) Representative images of SCF immunofluorescence in NP epithelium. Arrow 644 
denotes SCF+ immunoreactivity. (B) Quantitative SCF immunohistomorphometry.  645 
(C) %tryptase+ hMMC in organ cultured human NPs (1 day). AEA, ACEA: 30 M, 646 
AM251: 1 M, anti-SCF neutralizing antibody: 1 g/ml. These experiments were from 647 
2 individuals. *P<0.05, ***P<0.001. 648 
649 
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 Supplementary Material and Methods 669 
 670 
Reagents 671 
N-arachidonoylethanolamine (AEA), arachidonyl-2-chloroethylamide (ACEA), 672 
N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4- 673 
chlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), substance P, 674 
compound 48/80 and corticotropin-releasing hormone (CRH) were purchased from 675 
Sigma-Aldrich (Taufkirchen, Germany), whereas 5-carboxytetramethylrhodamine 676 
(5-TAMRA) conjugated AM251, Tocrifluor was from Tocris Bioscience (Bristol, UK). 677 
SCF- neutralizing antibody was from R&D systems (R&D systems, Minneapolis, MN). 678 
The sources of the primary antibodies used for 679 
immunohistochemistry/immunofluorescence are indicated below. 680 
 681 
Histochemistry 682 
Histochemistry for collagen fibers was performed according to manufacture’s protocol 683 
(modified Verhoeff Van Gieson stain, Elastic stain Kit, Sigma). For PAS staining, 684 
deparaffinized sections were incubated with 1% periodic acid at RT (room 685 
temperature) for 10 min. After a wash, the sections were incubated with Schiff’s 686 
reagent (Merck, Darmstadt, Germany) at RT for 15 min, followed by a wash with tap 687 
water. Then, the sections were counterstained by Hematoxylin. Leder’s esterase 688 
histochemistry was performed with cryo-embeded sections as previously reported.E1 689 
 690 
We define a mast cell (MC) as “degranulated”, when 5 or more histochemically or 691 
immunohistologically identified MC granules are seen to be located clearly outside the 692 
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cell membrane. Although a cut-off set at 5 extracellular MC granules is evidently 693 
arbitrary and likely only captures MCs that are undergoing “anaphylactic” MC 694 
degranulation,E2 this simple, but pragmatic and easily reproducible morphometric 695 
technique has proven very instructive and sensitive in multiple previous MC in situ 696 
studies that we and others have published in murine and human skin. 697 
 698 
 699 
Immunohistochemistry/Immunofluorescence microscopy 700 
For the detection of Kit, tryptase and chymase, deparaffinized sections were 701 
antigen-retrieved by microwave (650 W, 20 minutes [min]). After the pre-incubation 702 
with either 5% normal goat serum + 1% BSA in 0.05 M Tris–HCl buffered saline (TBS) 703 
(RT, 60 min, for Kit) or 0.5% triton-X in 6% BSA in TBS (RT, 30 min, for chymase, 704 
tryptase and FcRI), sections were incubated overnight at 4°C with primary 705 
antibodies, rabbit anti-human CD117 (DAKO, Hamburg, Germany) at 1:100, mouse 706 
anti-human chymase (Abcam plc, Cambridge, UK) at 1:100, mouse anti-FcRI (Acris 707 
Antibodies GmbH, Herford, Germany) at 1:100, or mouse anti-human tryptase 708 
(Abcam plc) at 1:500 diluted in antibody diluent (DCS Innovative Diagnostik-Systeme, 709 
Hamburg, Germany). Thereafter, the sections were incubated with goat biotinylated 710 
antibodies against rabbit or mouse IgG (Jackson Immunoresearch Laboratories, West 711 
Grove, PA) at 1:200 in antibody diluents (DCS Innovative Diagnostik-Systeme) for 45 712 
min at RT. Sections were then treated with the alkaline phosphatase-based 713 
avidin-biotin complex (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA) 714 
and the expression of these antigens was visualized by Fast Red (Sigma).  715 
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For the detection of cannabinoid receptor 1 (CB1), after deparaffinization and 716 
antigen-retrieval, the sections were pretreated with avidin and biotin (Blocking Kit, 717 
Vector Laboratories) to block the endogenous avidin and biotin. After the overnight 718 
incubation with the primary anti-CB1 antibody (Santa Cruz, 1:50 in antibody diluents), 719 
the sections were treated by alkaline phosphatase-based labeled streptoavidin biotin 720 
method (DCS Innovative Diagnostik-Systeme) and CB1 expression was visualized by 721 
Fast Red (Sigma).  722 
 723 
Double-immunostaining for Kit and CB1 was performed by using the tyramide signal 724 
amplification (TSA) technique (Perkin Elmer, Boston, MA).E1 725 
 726 
For double-immunohistochemistry for Kit and FcRI, the sections were first 727 
deparaffinized and antigen-retrieved by microwave. After the overnight incubation with 728 
mouse anti-FcRI at 1:100 (at 4°C), slides were incubated with biotin conjugated 729 
goat anti-mouse IgG at 1:200 for 45 min (at RT). Sections were then treated by 730 
HRP-based avidin-biotin complex (Vectastain Elite ABC kit; Vector Laboratories) and 731 
FcRI expression was visualized by DAB (Dako). After the careful wash, the sections 732 
were then overnight-incubated with rabbit anti-CD117 antibody at 1:100 (at 4°C). 733 
Thereafter, the sections were incubated with goat biotinylated antibodies against 734 
rabbit IgG (Jackson Immunoresearch Laboratories) at 1:200 for 45 min at RT. 735 
Sections were then treated with the alkaline phosphatase-based avidin-biotin complex 736 
(Vectastain Elite ABC kit; Vector Laboratories) and the expression of these antigens 737 
was visualized by Fast Red (Sigma). 738 
 739 
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To study the proliferation or apoptosis of the Kit+ cells, double-immunostaining for 740 
Ki67 and Kit or Kit immunostaining and terminal dUTP nick-end labeling (TUNEL) was 741 
performed on the same cryo-embeded sections as we have previously shown.E1  742 
For detecting SCF in cryo-embeded organ cultured human NPs, an indirect 743 
immunofluorescence method was applied,E1 while alkaline phosphatase-based 744 
avidin-biotin method was performed on paraffin-embedded sections using rabbit 745 
anti-human SCF antibody at 1:50 (Santa Cruz) and the expression of the antigen was 746 
visualized by Fast Red (Sigma). 747 
For detecting double+ cells for tryptase and chymase within human NPs, the 748 
double-immunostaining could not be successfully performed since the primary 749 
antibodies for tryptase and chymase were from same species. Therefore, we 750 
performed these immunostaining separately using a pair of“mirror image” sections, so 751 
that we could take advantage of the possible detection of two different staining 752 
patterns in exactly the same cell within the tissue.E3 753 
 754 
Quantitative immunohistomorphometry 755 
Antigen expression was quantified by assessing the immunoreactivity in defined 756 
reference areas was assessed by quantitative immunohistomorphometryE1 using the 757 
ImageJ software (National Institutes of Health, Bethesda, MD). 758 
 759 
High resolution light microscopy (HRLM) and Transmission electron 760 
microscopy (TEM) 761 
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Thin and thick sections of organ cultured human NPs were generated as previously 762 
reported.E1 1 m of thick sections were prepared for an alkaline Giemsa 763 
histochemistry,E1 while thin sections were stained with uranyl acetate and lead citrate 764 
and observed with an electron microscope (JEM-1200EXII, JEOL, Tokyo, Japan).E1 765 
 766 
LDH measurement 767 
Lactate dehydrogenase (LDH) activity in the culture medium was measured according 768 
to the manufacturer's instructions (Cytotoxicity Detection Kit, Roche Mannheim, 769 
Germany) as a biochemical indicator of tissue viability.E4 The absorbance of the 770 
samples was measured at 490 nm using an ELISA reader.  771 
 772 
CB1 knock-down in situ 773 
All reagents required for transfection (human CB1 siRNA (sc-39910), control 774 
(scrambled, SCR) siRNA (sc-37007), siRNA transfection reagent (sc-29528) and 775 
siRNA transfection Medium (sc-36868)) were obtained from Santa Cruz. Transfection 776 
(6 hrs) with isolated human NPs was performed as described previously.E1   777 
 778 
 779 
780 
Sugawara et al 
39 
 
Supplementary texts 781 
S1. Giannini et alE5 reported that a non-selective CB1/CB2 agonist (CP55,940) 782 
prevented antigen-induced asthma-like reaction in guinea pigs and that this effect was 783 
abrogated by the treatment with either CB1 or CB2  antagonists. Interestingly, the 784 
degranulation-protective effect of CP55,940 on guinea pig lung MCs was abrogated 785 
by co-administration of the CB1 specific antagonist, AM251, but not by a CB2-specific 786 
antagonist. Yet, the authors concluded that both receptors might be important to 787 
inhibit guinea pig lung MC degranulation.E5 788 
 789 
S2. While MCs represent by far the largest c-Kit+ cell population in human and murine 790 
skin mesenchyme, it was unclear whether this also applies to human NPs. However, 791 
FcRI and Kit double-immunohistochemistry (Fig. E1D) revealed that, 71.3% of Kit+ 792 
cells co-expressed FcRI in freshly microdissected human NP samples (n=3). 793 
Therefore, most Kit+ cells in human NP stroma clearly represent hMMCs. hMMCs 794 
have been reported to express tryptase, but not chymase.E6,7 However, human 795 
tissues display mixed MC sub-types, and MC distribution, which are not as clearly 796 
demarcated as in rodents.E8 Indeed, in freshly isolated human NP samples, the ratio 797 
of MCT (tryptase+, chymase- MCs; which likely represent T-cell dependent mucosal 798 
MCsE9) versus MCTC (tryptase+, chymase+) was 76.87% : 23.13% in epithelium, 799 
while that in lamina propria was 66.85% : 33.15% detected by tryptase or chymase 800 
immunohistochemistry using “Mirror image” sections (see supplementary Methods) 801 
(from 2 individuals) (Fig. E1E). 802 
 803 
 804 
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Supplementary Figure legend  835 
FIG E1. hMMCs are detectable by MC immunohistochemistry during the organ culture 836 
(A) tryptase+degranulated MC. yellow allows: MC granules outside cell membrane. 837 
(B) LDH assay. (C) hMMCs (alkaline Giemsa histochemistry) (D) Kit/FcRI 838 
immunohistochemistry. Black arrows: FcRI+ cells. Red arrow: Kit+ cells. Yellow 839 
arrow: double+ cell. (E) tryptase/chymase “mirror image”-immunohistochemistry. Red 840 
arrow: tryptase+ chymase- cells. Yellow arrows: double+ cells. Quantitative tryptase 841 
(F), Kit (G) immunohistomorphometry. From 3 individuals. *P<0.05, **P<0.01, 842 
***P<0.001, N.S.=not significant. 843 
 844 
FIG E2. CB1 inhibition promotes the degranulation of hMMCs in NPs. 845 
 (A) Quantitative Ki67/Kit immunohistomorphometry. (B and C) Quantitative tryptase 846 
immnuohistomorphometry (D) Quantitative alkaline Giemsa histomorphometry of 847 
hMMCs. (E) Transmission electron microscopy of hMMCs. Yellow arrow: 848 
Non-degranulated hMMC. Red arrow: Degranulated hMMC. Quantitative Kit (G) and 849 
chymase (H) immunohistomorphometry Data were from 2-3 individuals. *P<0.05, 850 
**P<0.01, ***P<0.001, N.S.=not significant. 851 
 852 
FIG E3. CB1 inhibition increased the percentage of tryptase+ hMMCs in all samples 853 
examined 854 
Tryptase immunohistomorphometry. *P<0.05, **P<0.01. 855 
 856 
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FIG E4. CB1 inhibition induced tryptase+ hMMCs degranulation in all samples 857 
examined 858 
Tryptase immunohistomorphometry. *P<0.05, **P<0.01, ***P<0.001. 859 
 860 
FIG E5. CB1 inhibition increased the percentages of Kit+ and chymase+ hMMCs in all 861 
samples examined 862 
Left side: Quantitative Kit immunohistomorphometry of organ cultured human NP 863 
samples treated with either vehicle or AM251 (1 M). 864 
Right side: Quantitative chymase immunohistomorphometry of organ cultured human 865 
NP samples treated with either vehicle or AM251 (1 M). *P<0.05, **P<0.01. 866 
 867 
FIG E6. CB1 inhibition induced edema in lamina propria within organ cultured human 868 
NPs 869 
(A) Representative images on cellularity (by tryptase immunohistochemistry) of organ 870 
cultured human NPs treated with either vehicle (control) or AM251. Red arrows 871 
indicate tryptase+ cells. Quantitative analysis of cellularity in lamina propria (B).  872 
***P<0.001. These experiments were from 2-3 individuals. 873 
 874 
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